No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NTBL Notable Labs
- 0.965
- +0.005+0.51%
Close Apr 26 16:00 ET
- 0.965
- -0.001-0.05%
Pre 08:00 ET
8.70MMarket Cap-282P/E (TTM)
1.070High0.950Low143.44KVolume0.980Open0.960Pre Close140.71KTurnover144.16%Turnover RatioLossP/E (Static)9.02MShares11.20052wk High0.58P/B96.02KFloat Cap0.83352wk Low--Dividend TTM99.50KShs Float595.826Historical High--Div YieldTTM12.49%Amplitude0.833Historical Low0.980Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | JMP Securities Reiterates Market Outperform on Notable Labs, Maintains $9 Price Target
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Farg
Express News | Notable Labs Ltd : Chardan Capital Markets Cuts Target Price to $7 From $9
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
Notable Labs Is Maintained at Buy by Chardan Capital
Notable Labs Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $7
Comments
$Notable Labs(NTBL.US$
NEWS
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Notable Labs, presents the design for a Phase 2 trial with volasertib and decitabine in patients with relapsed/refractory AML at AACR 2024. The company aims to predict responders using their PPMP and develop a companion diagnostic test.
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to p...
NEWS
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Notable Labs, presents the design for a Phase 2 trial with volasertib and decitabine in patients with relapsed/refractory AML at AACR 2024. The company aims to predict responders using their PPMP and develop a companion diagnostic test.
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to p...
1
1
😳
$Opko Health(OPK.US$ CEO and Co-founder Mr Frost bought 1 million shares 1 week before earnings out. Keep a watch on this.. Fishy!
Below are some stocks on my watchlist.
$Semilux(SELX.US$
$WiSA Technologies(WISA.US$
$Aesthetic Medical International(AIH.US$
$Inspire Veterinary Partners(IVP.US$
$Transcode Therapeutics(RNAZ.US$
$Biodexa Pharmaceuticals(BDRX.US$
$HUB Cyber Security(HUBC.US$
$Tian Ruixiang(TIRX.US$
$Inpixon(INPX.US$
$Treasure Global(TGL.US$
$Golden Heaven(GDHG.US$
$Next.e.GO(EGOX.US$
...
Below are some stocks on my watchlist.
$Semilux(SELX.US$
$WiSA Technologies(WISA.US$
$Aesthetic Medical International(AIH.US$
$Inspire Veterinary Partners(IVP.US$
$Transcode Therapeutics(RNAZ.US$
$Biodexa Pharmaceuticals(BDRX.US$
$HUB Cyber Security(HUBC.US$
$Tian Ruixiang(TIRX.US$
$Inpixon(INPX.US$
$Treasure Global(TGL.US$
$Golden Heaven(GDHG.US$
$Next.e.GO(EGOX.US$
...
2
3
Will it take off soon?
$Notable Labs(NTBL.US$ The BB is tightening on 24H, looks like a consolidation is ongoing before is breaks. Shorts volume is high compared to the remaining shares for shorting. Days to cover are still considered short at 2.9 days before the shorts can be squeezed. I am going to take a gamble and entering at 1.18. I am speculating that the worst scenario will be price plunging to 0.6 to 0.7 range but if it takes off, it should be at least +150%.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
luckme : 他还没启动，最小的迷你股，很容易控盘